Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
ATARA Biotherapeutics (ATRA) Tops Q3 EPS by 4c
November 4, 2021 7:39 AM EDTATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.90), $0.04 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $3.92 million.
For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.
... More